CD8A and melanoma: In patients with stage III or IV melanoma, the immunostimulant mRNA vaccine TriMix, expressing CD70, CD40L, and a constitutively active version of TLR4, elicited robust CD8+ T cell responses and demonstrated improved immune response rates in a phase II clinical trial [68].